<u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

| Antibodies | Yes (indicate where provided: section/paragraph) | n/a |
|---|--|-------|
| For commercial reagents, provide supplier | Paragraph 10 of Method | |
| name, catalogue number and RRID, if available. | | |
| Cell materials | Yes (indicate where provided: section/paragraph) | n/a |
| Cell lines: Provide species information, strain. | Paragraph 2 of Method | 11/ d |
| Provide accession number in repository OR | | |
| supplier name, catalog number, clone number, | | |
| OR RRID | | |
| Primary cultures: Provide species, strain, sex of | Paragraph 2-8 of Method | |
| origin, genetic modification status. | | |
| Experimental animals | Yes (indicate where provided: section/paragraph) | n/a |
| Laboratory animals: Provide species, strain, sex, age, | This study has no animal. | |
| genetic modification status. Provide accession | | |
| number in repository OR supplier name, catalog | | |
| number, clone number, OR RRID | | |
| Animal observed in or captured from the | This study has no animal. | |
| field: Provide species, sex and age where | | |
| possible | | |
| Model organisms: Provide Accession number | We're not using model organisms. | |
| in repository (where relevant) OR RRID | | |
| Plants and microbes | Yes (indicate where provided: section/paragraph) | n/a |
| Plants: provide species and strain, unique accession | This study has not using plants. | |
| number if available, and source (including location | | |
| for collected wild specimens) | | |
| Microbes: provide species and strain, unique | This study has not using microbes. | |
| accession number if available, and source | , , , | |
| Human research participants | Yes (indicate where provided: section/paragraph) | n/a |
| Identify authority granting ethics approval (IRB or | Paragraph 1 of Method | |
| equivalent committee(s), provide reference number | | |
| for approval. | | |
| Provide statement confirming informed consent | Paragraph 1 of Method | |
| obtained from study participants. | | |
| Report on age and sex for all study participants. | Paragraph 1 of Method | |

<u>Design</u>

| Study protocol | Yes (indicate where provided: section/paragraph) | n/a |
|---|--|-------|
| For clinical trials, provide the trial registration | There are no clinical trials. | |
| number OR cite DOI in manuscript. | | |
| Laboratory protocol | Yes (indicate where provided: section/paragraph) | n/a |
| Provide DOI or other citation details if detailed step- | Paragraph 1-10 of Methods | , a |
| by-step protocols are available. | · · · · · · · · · · · · · · · · · · · | |
| Experimental study design (statistics details) | Yes (indicate where provided: section/paragraph) | n/a |
| State whether and how the following have been | Paragraph 11 of Method | 11/ 4 |
| done, or if they were not carried out. | | |
| Sample size determination | Paragraph 1-10 of Methods | |
| Randomisation | Paragraph 1-10 of Methods | |
| Blinding | unused | |
| Inclusion/exclusion criteria | unused | |
| • | | |
| Sample definition and in-laboratory replication | Yes (indicate where provided: section/paragraph) | n/a |
| State number of times the experiment was | Paragraph 11 of Method | |
| replicated in laboratory | | |
| Define whether data describe technical or biological | Paragraph 11 of Method | |
| replicates | | |
| Ethics | Yes (indicate where provided: section/paragraph) | n/a |
| Studies involving human participants: State details of | Paragraph 1 of Method | |
| authority granting ethics approval (IRB or equivalent | | |
| committee(s), provide reference number for | | |
| approval. | | |
| Studies involving experimental animals: State details | No animal. | |
| of authority granting ethics approval (IRB or | | |
| equivalent committee(s), provide reference number | | |
| for approval. | | |
| Studies involving specimen and field samples: State if | Not from the field. | |
| relevant permits obtained, provide details of | | |
| authority approving study; if none were required, | | |
| explain why. | | |
| Dual Use Research of Concern (DURC) | Yes (indicate where provided: section/paragraph) | n/a |
| If study is subject to dual use research of concern, | Not applicable to DURC. | , a |
| state the authority granting approval and reference | | |
| | | |

<u>Analysis</u>

| Attrition | Yes (indicate where provided: section/paragraph) | n/a |
|---|--|-----|
| State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance. | Paragraph 11 of Method | |
| Statistics | Yes (indicate where provided: section/paragraph) | n/a |
| Describe statistical tests used and justify choice of tests. | Paragraph 11 of Method | |
| Data Availability | Yes (indicate where provided: section/paragraph) | n/a |
| State whether newly created datasets are available, including protocols for access or restriction on access. | No datasets. | |
| If data are publicly available, provide accession number in repository or DOI or URL. | The datasets are not available. | |
| If publicly available data are reused, provide accession number in repository or DOI or URL, where possible. | No datasets. | |
| Code Availability | Yes (indicate where provided: section/paragraph) | n/a |
| For all newly generated code and software essential for replicating the main findings of the study: | No code or software. | |
| State whether the code or software is available. | The code or software is not available. | |
| If code is publicly available, provide accession number in repository, or DOI or URL. | No code or software. | |

Reporting

| Adherence to community standards | Yes (indicate where provided: section/paragraph) | n/a |
|---|--|-----|
| MDAR framework recommends adoption of | We have followed the discipline-specific guidelines. | |
| discipline-specific guidelines, established and | | |
| endorsed through community initiatives. Journals | | |
| have their own policy about requiring specific | | |
| guidelines and recommendations to complement | | |
| MDAR. | | |
| State if relevant guidelines (eg., ICMJE, MIBBI, | ICMJE guidelines were followed, as the journal follows | |
| ARRIVE) have been followed, and whether a checklist | ICMJE recommendations for publication. | |
| (eg., CONSORT, PRISMA, ARRIVE) is provided with | | |
| the manuscript. | | |

Article information: http://dx.doi.org/10.21037/atm-20-7365